Page last updated: 2024-12-07

b 823-08

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

B 823-08: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128828
CHEBI ID80011
SCHEMBL ID3911587
MeSH IDM0142302

Synonyms (13)

Synonym
86604-69-5
b 823-08
by 308
2-[(4-methoxy-3-methylpyridin-2-yl)methylsulfanyl]-6-(trifluoromethyl)-1h-benzimidazole
2-((4-methoxy-3-methyl-2-pyridylmethyl)sulfo)-5-trifluoromethyl-1h-benzimidazole
by-308
b-823-08
1h-benzimidazole, 2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)thio)-5-(trifluoromethyl)-
SCHEMBL3911587
CHEBI:80011
DTXSID00235693
Q27149158
cexguucqsxkhrs-uhfffaoysa-n

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Based on the experience from more than 10,000 individuals omeprazole has been found to be safe and is well tolerated."( Omeprazole: long-term safety.
Arnold, R; Koop, H, 1989
)
0.28

Dosage Studied

ExcerptRelevanceReference
" This gastrin-carcinoid sequence is unlikely to occur in man with an omeprazole dosage recommended for treatment of peptic diseases."( Omeprazole: long-term safety.
Arnold, R; Koop, H, 1989
)
0.28
" Increasing concentrations of PD 136450 caused a monophasic dose-response curve in contrast to the well-known biphasic amylase release in response to CCK8."( A new CCK-B/gastrin receptor antagonist acts as an agonist on the rat pancreas.
Arnold, R; Eissele, R; Koop, H; Koop, I; Meyer, F; Mössner, J; Patberg, H; Richter, S, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (50.00)18.7374
1990's4 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]